Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Date
This Form 8-K, filed December 19, 2023 under Item 8.01, reports changes to the exercise price and issuance status of certain outstanding and prospective warrants. Neuraxis, Inc. is a Delaware corporation whose common stock trades on the NYSE American under the symbol NRXS.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- The Company previously issued 2022 Warrants exercisable for 793,655 common shares and 2023 Warrants exercisable for 505,570 common shares, generally at an exercise price of $5.25 per share.
- The Company also issued 120,235 placement-agent warrants with terms matching the 2023 Warrants. These placement-agent warrant shares were not registered in the August 2023 registration statement.
- Under a securities purchase agreement with Flagstaff International, LLC for Series B Convertible Preferred Stock priced at $2.38 per share, the exercise price of the applicable warrants was adjusted to $2.38 per share.
- As of December 19, 2023, Flagstaff had not paid for or received any Series B Preferred Stock.
- As of the filing date, the Company had not issued new 2023 Warrants covering 609,760 common shares or new placement-agent warrants covering 144,990 common shares under the applicable adjustment provisions. The number of shares issuable under the 2022 Warrants remained unchanged.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. Key risks include the potential dilution from warrant exercises at the reduced $2.38 exercise price, uncertainty regarding the completion or funding of the Flagstaff preferred-stock transaction, and the unregistered status of the placement-agent warrant shares. The filing text does not clearly explain the relationship between the previously stated 2023 Warrant share count of 505,570 and the later reference to 609,760 new 2023 Warrant shares.
Investor Verification Items
- Verify whether Flagstaff International ultimately funded and received the Series B Preferred Stock.
- Confirm the final number of warrants outstanding, issued, adjusted, and exercisable at $2.38 per share.
- Assess potential common-stock dilution from the 2022 Warrants, 2023 Warrants, and placement-agent warrants.
- Review subsequent SEC filings for registration of the placement-agent warrant shares and any changes to the warrant terms.